Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Earnings and Valuation
This table compares Bicara Therapeutics and Compass Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bicara Therapeutics | N/A | N/A | -$137.95 million | ($2.53) | -9.13 |
| Compass Therapeutics | N/A | N/A | -$66.49 million | ($0.43) | -12.19 |
Risk & Volatility
Bicara Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for Bicara Therapeutics and Compass Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bicara Therapeutics | 1 | 3 | 8 | 0 | 2.58 |
| Compass Therapeutics | 1 | 0 | 11 | 1 | 2.92 |
Bicara Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 21.16%. Compass Therapeutics has a consensus target price of $13.11, indicating a potential upside of 150.21%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Bicara Therapeutics.
Profitability
This table compares Bicara Therapeutics and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bicara Therapeutics | N/A | -32.49% | -30.87% |
| Compass Therapeutics | N/A | -43.61% | -38.05% |
Insider & Institutional Ownership
68.4% of Compass Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Compass Therapeutics beats Bicara Therapeutics on 9 of the 12 factors compared between the two stocks.
About Bicara Therapeutics
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
